CN102973896A - 一种治疗肿瘤的中药组合物 - Google Patents
一种治疗肿瘤的中药组合物 Download PDFInfo
- Publication number
- CN102973896A CN102973896A CN2012105431014A CN201210543101A CN102973896A CN 102973896 A CN102973896 A CN 102973896A CN 2012105431014 A CN2012105431014 A CN 2012105431014A CN 201210543101 A CN201210543101 A CN 201210543101A CN 102973896 A CN102973896 A CN 102973896A
- Authority
- CN
- China
- Prior art keywords
- gram
- grams
- chinese medicine
- medicine composition
- traditional chinese
- Prior art date
Links
- 239000003814 drugs Substances 0.000 title claims abstract description 32
- 239000000203 mixtures Substances 0.000 title claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 6
- 239000002994 raw materials Substances 0.000 claims abstract description 6
- 241000218176 Corydalis Species 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims description 4
- 241001312741 Gekko swinhonis Species 0.000 claims description 4
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 4
- 229940097275 Indigo Drugs 0.000 claims description 4
- 240000007871 Indigofera tinctoria Species 0.000 claims description 4
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 4
- 241001057584 Myrrha Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 241000237636 Pheretima Species 0.000 claims description 4
- 241000195474 Sargassum Species 0.000 claims description 4
- 241000131808 Scolopendra Species 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 2
- 238000002360 preparation methods Methods 0.000 abstract description 2
- NVIPUOMWGQAOIT-RQOWECAXSA-N (Z)-7-Hexadecen-1,16-olide Chemical class data:image/svg+xml;base64,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 data:image/svg+xml;base64,PD94bWwgdmVyc2lvbj0nMS4wJyBlbmNvZGluZz0naXNvLTg4NTktMSc/Pgo8c3ZnIHZlcnNpb249JzEuMScgYmFzZVByb2ZpbGU9J2Z1bGwnCiAgICAgICAgICAgICAgeG1sbnM9J2h0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnJwogICAgICAgICAgICAgICAgICAgICAgeG1sbnM6cmRraXQ9J2h0dHA6Ly93d3cucmRraXQub3JnL3htbCcKICAgICAgICAgICAgICAgICAgICAgIHhtbG5zOnhsaW5rPSdodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rJwogICAgICAgICAgICAgICAgICB4bWw6c3BhY2U9J3ByZXNlcnZlJwp3aWR0aD0nODVweCcgaGVpZ2h0PSc4NXB4JyB2aWV3Qm94PScwIDAgODUgODUnPgo8IS0tIEVORCBPRiBIRUFERVIgLS0+CjxyZWN0IHN0eWxlPSdvcGFjaXR5OjEuMDtmaWxsOiNGRkZGRkY7c3Ryb2tlOm5vbmUnIHdpZHRoPSc4NScgaGVpZ2h0PSc4NScgeD0nMCcgeT0nMCc+IDwvcmVjdD4KPHBhdGggY2xhc3M9J2JvbmQtMCcgZD0nTSA3Ni45NjQ0LDQwLjgyMDUgTCA3MS45ODUxLDQwLjgyMDUnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiNFODQyMzU7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0wJyBkPSdNIDcxLjk4NTEsNDAuODIwNSBMIDY3LjAwNTgsNDAuODIwNScgc3R5bGU9J2ZpbGw6bm9uZTtmaWxsLXJ1bGU6ZXZlbm9kZDtzdHJva2U6IzNCNDE0MztzdHJva2Utd2lkdGg6MnB4O3N0cm9rZS1saW5lY2FwOmJ1dHQ7c3Ryb2tlLWxpbmVqb2luOm1pdGVyO3N0cm9rZS1vcGFjaXR5OjEnIC8+CjxwYXRoIGNsYXNzPSdib25kLTAnIGQ9J00gNzYuOTY0NCw0My4xNzk1IEwgNzEuOTg1MSw0My4xNzk1JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojRTg0MjM1O3N0cm9rZS13aWR0aDoycHg7c3Ryb2tlLWxpbmVjYXA6YnV0dDtzdHJva2UtbGluZWpvaW46bWl0ZXI7c3Ryb2tlLW9wYWNpdHk6MScgLz4KPHBhdGggY2xhc3M9J2JvbmQtMCcgZD0nTSA3MS45ODUxLDQzLjE3OTUgTCA2Ny4wMDU4LDQzLjE3OTUnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xJyBkPSdNIDY3LjAwNTgsNDIgTCA2NC44Mzg1LDMwLjQwNjInIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xNycgZD0nTSA2Ny4wMDU4LDQyIEwgNjYuMTA1OSw0Ni44MTQnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xNycgZD0nTSA2Ni4xMDU5LDQ2LjgxNCBMIDY1LjIwNiw1MS42MjgnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiNFODQyMzU7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0yJyBkPSdNIDY0LjgzODUsMzAuNDA2MiBMIDU4LjYyOTQsMjAuMzc4Micgc3R5bGU9J2ZpbGw6bm9uZTtmaWxsLXJ1bGU6ZXZlbm9kZDtzdHJva2U6IzNCNDE0MztzdHJva2Utd2lkdGg6MnB4O3N0cm9rZS1saW5lY2FwOmJ1dHQ7c3Ryb2tlLWxpbmVqb2luOm1pdGVyO3N0cm9rZS1vcGFjaXR5OjEnIC8+CjxwYXRoIGNsYXNzPSdib25kLTMnIGQ9J00gNTguNjI5NCwyMC4zNzgyIEwgNDkuMjE3MSwxMy4yNzA0JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojM0I0MTQzO3N0cm9rZS13aWR0aDoycHg7c3Ryb2tlLWxpbmVjYXA6YnV0dDtzdHJva2UtbGluZWpvaW46bWl0ZXI7c3Ryb2tlLW9wYWNpdHk6MScgLz4KPHBhdGggY2xhc3M9J2JvbmQtNCcgZD0nTSA0OS4yMTcxLDEzLjI3MDQgTCAzNy44NzI4LDEwLjA0MjYnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC01JyBkPSdNIDM3Ljg3MjgsMTAuMDQyNiBMIDI2LjEyODQsMTEuMTMwOScgc3R5bGU9J2ZpbGw6bm9uZTtmaWxsLXJ1bGU6ZXZlbm9kZDtzdHJva2U6IzNCNDE0MztzdHJva2Utd2lkdGg6MnB4O3N0cm9rZS1saW5lY2FwOmJ1dHQ7c3Ryb2tlLWxpbmVqb2luOm1pdGVyO3N0cm9rZS1vcGFjaXR5OjEnIC8+CjxwYXRoIGNsYXNzPSdib25kLTYnIGQ9J00gMjYuMTI4NCwxMS4xMzA5IEwgMTUuNTcwMywxNi4zODgyJyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojM0I0MTQzO3N0cm9rZS13aWR0aDoycHg7c3Ryb2tlLWxpbmVjYXA6YnV0dDtzdHJva2UtbGluZWpvaW46bWl0ZXI7c3Ryb2tlLW9wYWNpdHk6MScgLz4KPHBhdGggY2xhc3M9J2JvbmQtNycgZD0nTSAxNS41NzAzLDE2LjM4ODIgTCA3LjYyNDM1LDI1LjEwNDUnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC03JyBkPSdNIDE2LjEyMTcsMTkuMjg0OCBMIDEwLjU1OTUsMjUuMzg2Mycgc3R5bGU9J2ZpbGw6bm9uZTtmaWxsLXJ1bGU6ZXZlbm9kZDtzdHJva2U6IzNCNDE0MztzdHJva2Utd2lkdGg6MnB4O3N0cm9rZS1saW5lY2FwOmJ1dHQ7c3Ryb2tlLWxpbmVqb2luOm1pdGVyO3N0cm9rZS1vcGFjaXR5OjEnIC8+CjxwYXRoIGNsYXNzPSdib25kLTgnIGQ9J00gNy42MjQzNSwyNS4xMDQ1IEwgMy4zNjM2NCwzNi4xMDI3JyBzdHlsZT0nZmlsbDpub25lO2ZpbGwtcnVsZTpldmVub2RkO3N0cm9rZTojM0I0MTQzO3N0cm9rZS13aWR0aDoycHg7c3Ryb2tlLWxpbmVjYXA6YnV0dDtzdHJva2UtbGluZWpvaW46bWl0ZXI7c3Ryb2tlLW9wYWNpdHk6MScgLz4KPHBhdGggY2xhc3M9J2JvbmQtOScgZD0nTSAzLjM2MzY0LDM2LjEwMjcgTCAzLjM2MzY0LDQ3Ljg5NzMnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xMCcgZD0nTSAzLjM2MzY0LDQ3Ljg5NzMgTCA3LjYyNDM1LDU4Ljg5NTUnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xMScgZD0nTSA3LjYyNDM1LDU4Ljg5NTUgTCAxNS41NzAzLDY3LjYxMTgnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xMicgZD0nTSAxNS41NzAzLDY3LjYxMTggTCAyNi4xMjg0LDcyLjg2OTEnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xMycgZD0nTSAyNi4xMjg0LDcyLjg2OTEgTCAzNy44NzI4LDczLjk1NzQnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xNCcgZD0nTSAzNy44NzI4LDczLjk1NzQgTCA0OS4yMTcxLDcwLjcyOTYnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xNScgZD0nTSA0OS4yMTcxLDcwLjcyOTYgTCA1OC42Mjk0LDYzLjYyMTgnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xNicgZD0nTSA1OC42Mjk0LDYzLjYyMTggTCA2MS4xMjU0LDU5LjU5MDcnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiMzQjQxNDM7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8cGF0aCBjbGFzcz0nYm9uZC0xNicgZD0nTSA2MS4xMjU0LDU5LjU5MDcgTCA2My42MjE0LDU1LjU1OTYnIHN0eWxlPSdmaWxsOm5vbmU7ZmlsbC1ydWxlOmV2ZW5vZGQ7c3Ryb2tlOiNFODQyMzU7c3Ryb2tlLXdpZHRoOjJweDtzdHJva2UtbGluZWNhcDpidXR0O3N0cm9rZS1saW5lam9pbjptaXRlcjtzdHJva2Utb3BhY2l0eToxJyAvPgo8dGV4dCBkb21pbmFudC1iYXNlbGluZT0iY2VudHJhbCIgdGV4dC1hbmNob3I9InN0YXJ0IiB4PSc3Ny4zNTc2JyB5PSc0Mi41ODk3JyBzdHlsZT0nZm9udC1zaXplOjNweDtmb250LXN0eWxlOm5vcm1hbDtmb250LXdlaWdodDpub3JtYWw7ZmlsbC1vcGFjaXR5OjE7c3Ryb2tlOm5vbmU7Zm9udC1mYW1pbHk6c2Fucy1zZXJpZjtmaWxsOiNFODQyMzUnID48dHNwYW4+TzwvdHNwYW4+PC90ZXh0Pgo8dGV4dCBkb21pbmFudC1iYXNlbGluZT0iY2VudHJhbCIgdGV4dC1hbmNob3I9InN0YXJ0IiB4PSc2My4zOTU3JyB5PSc1NC4xODM1JyBzdHlsZT0nZm9udC1zaXplOjNweDtmb250LXN0eWxlOm5vcm1hbDtmb250LXdlaWdodDpub3JtYWw7ZmlsbC1vcGFjaXR5OjE7c3Ryb2tlOm5vbmU7Zm9udC1mYW1pbHk6c2Fucy1zZXJpZjtmaWxsOiNFODQyMzUnID48dHNwYW4+TzwvdHNwYW4+PC90ZXh0Pgo8L3N2Zz4K O=C1CCCCC\C=C/CCCCCCCCO1 NVIPUOMWGQAOIT-RQOWECAXSA-N 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241001474374 Blennius Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 241000270288 Gekko Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 240000004678 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 239000010075 Qingdai compound Substances 0.000 abstract 1
- 210000003660 Reticulum Anatomy 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 210000002784 Stomach Anatomy 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 7
- 206010020039 Hiccups Diseases 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000011901 water Substances 0.000 description 5
- 239000002674 ointments Substances 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- 210000002318 Cardia Anatomy 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000005516 engineering processes Methods 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000722917 Cacosmia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 210000004222 Sensilla Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001276 controlling effects Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 diseases Diseases 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000003419 expectorant Effects 0.000 description 1
- 239000003172 expectorant agents Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000007789 gases Substances 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 239000007788 liquids Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000003921 oils Substances 0.000 description 1
- 235000019546 parosmia Nutrition 0.000 description 1
- 239000006072 pastes Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Abstract
本发明涉及一种治疗肿瘤的中药组合物，特别涉及一种恶性肿瘤的中药组合物。本发明的治疗恶性肿瘤的中药组合物，是由以下重量的原料制成，草乌15～18克，莪术5-9克，三棱5-9克，青代2-3克，蜂房10-15克，皂刺7-10克，没药1-1.5克，元寸7-9克，蜈蚣5-15克，川乌5-7克，蛇皮20-30克，守宫20-25克，双花10-12克，地龙2-5克，三七4-6克，元胡4-8克，白花蛇草15-20克，茵陈1-5克，连翘11-15克，海藻20-25克，昆布1-5克。综上所述，本发明的药物具有疗效显著，毒性小，原料配比少，制备方法简单。
Description
一种治疗肿瘤的中药组合物
技术领域
[0001] 本发明涉及一种治疗肿瘤的中药组合物，特别涉及一种治疗恶性肿瘤的中药组合物。
背景技术
[0002]目前，恶性肿瘤已成为人类的头号杀手，中医中药治疗癌症有成功的经验和独特的优势，特别是中医药非杀伤性疗法，在治疗恶性肿瘤中所表现的优势已为世人所瞩目。但现有的中药抗肿瘤药物，一般只能针对单一的恶性肿瘤起作用，不具有广泛的治疗作用，而且副作用较大。
发明内容
[0003] 本发明为了克服以上技术的不足，提供了一种治疗多种恶性肿瘤的纯中药组合物，并具有疗效显著，副作用小的特点。
[0004] 本发明是通过以下措施来实现的：
本发明的治疗肿瘤的中药组合物，是由以下重量的原料制成，
草乌15〜18克，莪术5-9克，三棱5-9克，青代2_3克，蜂房10-15克，皂刺7_10克，没药1-1. 5克，元寸7-9克，蜈蚣5-15克，川乌5-7克，蛇皮20-30克，守宫20-25克，双花10-12克，地龙2-5克，三七4-6克，元胡4-8克，白花蛇草15-20克，茵陈1_5克，连翘11-15克，海藻20-25克，昆布1-5克。
[0005] I.本发明的中药组合物的制备方法：
将上述药物粉碎混合后，加水煎煮两次，滤过，合并煎煮液，分为两份即可。
[0006] 用法：上述煎煮液，口服，早晚各一次。
[0007] 2.本发明的药物急性毒性实验
取小鼠20只，雌雄各半，体重16〜23g，口服给药，本发明的药物煎煮液浓缩成I : 2，O. 2ml/10g，2次/日，连续观察7天，动物无一死亡，且饮食、活动、背毛、粪便皆未见异常，处死小鼠，活检心、肝、脾、肺、肾亦未见异常，限于给药浓度的原因，无法测得LD5tl，该药最大耐受量至少相当于临床用量的120倍。
具体实施方式
[0008] 实施例I
本实施例的中药组合物，是由以下重量的原料组成。
[0009] 草乌15克，莪术5克，三棱5克，青代2克，蜂房10克，皂刺7克，没药I克，元寸7克，蜈蚣5克，川乌5克，蛇皮20克，守宫20克，双花10克，地龙2克，三七5克，元胡5克，白花蛇草15克，茵陈5克，连翘15克，海藻20克，昆布5克。
[0010] 将上述药物粉碎混合后，加水煎煮两次，滤过，合并煎煮液，分为两份即可。
[0011] 用法：上述煎煮液，口服，早晚各一次。[0012] 实施例2
本实施例的中药组合物，是由以下重量的原料组成。
[0013] 草乌18克，莪术9克，三棱8克，青代2克，蜂房10克，皂刺10克，没药I克，元寸7克，蜈蚣10克，川乌6克，蛇皮25克，守宫20克，双花11克，地龙4克，三七5克，元胡5克，白花蛇草15克，茵陈I克，连翘11克，海藻20克，昆布I克。
[0014] 将上述药物粉碎混合后，加水煎煮两次，滤过，合并煎煮液，分为两份即可。
[0015] 用法：上述煎煮液，口服，早晚各一次。
[0016] 临床试验病例 病例一 王明民，男，45岁，河南安阳人，于2009年11月22日上午9:15分被医院诊断为胃癌。其具体表现为：体瘦、面黄白、脸上有网状筋块、眼凸无神、有气无力、不能行走、不能呼吸冷空气、气逆、呃逆、声音特大、呕吐奇臭泡沫痰、胃部疼痛、贲门部位拒按、胃部上有大肿块、按之坚硬疼痛剧烈、不能进软食，进食则难下咽，咽下食物立即呕吐、一吐10-20分钟，闻油则呕吐、不戴口罩呼吸冷空气则呕吐，呕吐时食道胃部疼痛剧烈，舌苔黄厚、干裂、脉象浮数、大便稀少、小便黄浓，据多家大医院判定，只能活十数天，家属和患者本人均无心再求医治。
[0017] 取本发明实施例I所制得的药品进行医治；
内用药：服用内用药6片，开水化散口服，慢慢咽下，一日四次。
[0018] 外用药：将充分浸泡外用药的纱布敷贴在胃肿块及贲门所处位置的体表部，每次敷贴6小时,一日四次。
[0019] 患者经过三天用药，效果明显：能食米糊能进食。呕吐减缓，胃部、贲门部疼痛减少，连续内服药和外用药协同用药一个疗程即七天后，患者能独立行走。不戴口罩，呃逆呕吐减半。胃部、贲门部疼痛减轻，后经过6个疗程的连续治疗：患者面色正常，能食各种肉食，呃逆呕吐停止。行走上五楼不喘不呃逆，一气而上，消化正常。食道部胃部肿块全无，重按也五疼痛，舌苔正常，大小便正常，脉象平稳，后去原医院复查，已全部恢复健康。
[0020]病例二
何丽华，女，65岁，江苏南京人，被医院诊断为肝癌，具体表现为：全身发黄、面黄肌瘦、卧床不能动、肝区肿块特大、轻按则剧痛，有少量腹水，胃部肿块坚硬、不能进食、进食则呕吐、，呃逆吐癌痰、胀痛呻吟，大便稀溏、小便茶黄，舌苔黄厚，脉象浮无力。
[0021] 取本发明实施例2所制得的药品进行医治；
内用药：服用内用药6片，开水化散口服，慢慢咽下，一日四次。
[0022] 外用药：将充分浸泡外用药的纱布敷贴在肝区胃部所对应的体表处，每天疗每次敷贴6小时,一日四次。
[0023] 患者经过七天第一个疗程的治疗，整个病情好转，肿块疼痛减轻，肿块明显变小变软，可以进服汤食，呕吐减少，舌苔变薄，脉象浮而无力，大小便基本上无变化，三个疗程(二十一天)后患者基本上能独立下床，上厕所，九个疗程(六十三天后)，患者一切正常，可外出自理家务。
Claims (1)
1. 一种治疗肿瘤的中药组合物，其特征在于：是由以下质量的原料制成，草乌15〜18克，莪术5-9克，三棱5-9克，青代2_3克，蜂房10-15克，皂刺7_10克， 没药1-1. 5克，元寸7-9克，蜈蚣5-15克，川乌5-7克，蛇皮20-30克，守宫20-25克，双花 10-12克，地龙2-5克，三七4-6克，元胡4-8克，白花蛇草15-20克，茵陈1_5克，连翘11-15 克，海藻20-25克，昆布1-5克。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105431014A CN102973896A (zh) | 2012-12-16 | 2012-12-16 | 一种治疗肿瘤的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105431014A CN102973896A (zh) | 2012-12-16 | 2012-12-16 | 一种治疗肿瘤的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102973896A true CN102973896A (zh) | 2013-03-20 |
Family
ID=47848431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105431014A CN102973896A (zh) | 2012-12-16 | 2012-12-16 | 一种治疗肿瘤的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102973896A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103861079A (zh) * | 2014-03-14 | 2014-06-18 | 杨峻峻 | 一种清热止痛消瘤中药组合物 |
| CN104001149A (zh) * | 2014-05-27 | 2014-08-27 | 刘存兵 | 一种治疗放射损伤中药组合物及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101745065A (zh) * | 2008-12-12 | 2010-06-23 | 董振家 | 一种具有抗癌止痛作用的药物组合物 |
-
2012
- 2012-12-16 CN CN2012105431014A patent/CN102973896A/zh not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101745065A (zh) * | 2008-12-12 | 2010-06-23 | 董振家 | 一种具有抗癌止痛作用的药物组合物 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103861079A (zh) * | 2014-03-14 | 2014-06-18 | 杨峻峻 | 一种清热止痛消瘤中药组合物 |
| CN103861079B (zh) * | 2014-03-14 | 2015-05-20 | 杨峻峻 | 一种清热止痛消瘤中药组合物 |
| CN104001149A (zh) * | 2014-05-27 | 2014-08-27 | 刘存兵 | 一种治疗放射损伤中药组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705897B (zh) | 一种癌症止疼膏药 | |
| CN101757598B (zh) | 一种治疗肝脏晚期恶性肿瘤病证的中药组合物及其制备方法 | |
| CN101804166B (zh) | 一种治疗小儿皮炎湿疹的中药组合物 | |
| CN102091282B (zh) | 一种治疗慢性胃炎、胃溃疡的药物 | |
| US7005146B2 (en) | Complex prescription of chinese medicine for the treatment of extensive cancer | |
| CN101874874B (zh) | 一种治疗幽门螺旋菌相关性慢性胃炎的中药制剂及其制备方法 | |
| CN101693102A (zh) | 一种治疗脾胃不和、脘腹胀满病证的中药组合物及制备方法 | |
| CN102552637B (zh) | 治疗肩周炎的中药组合物及其制备方法 | |
| CN101773633A (zh) | 一种治疗胃溃疡的中药组合物及其制备方法 | |
| CN101785847A (zh) | 一种治疗肠癌的中药组合物及其制备方法 | |
| CN104367796B (zh) | 一种治疗口腔溃疡的中药组合物 | |
| CN101829294B (zh) | 一种治疗肺热病的中药组合物及其制备方法 | |
| CN101342333B (zh) | 一种治疗咳喘的中药及其制备方法 | |
| CN102988843B (zh) | 一种治疗慢性痛风性关节炎的中药痛风灵 | |
| CN103041317B (zh) | 一种治疗肿瘤的中药组合物及其制备方法 | |
| CN101773634A (zh) | 一种治疗脘腹痞满病的中药组合物及其制备方法 | |
| CN101249235B (zh) | 治疗食道癌的中药及其制备方法 | |
| CN102579940B (zh) | 一种治疗小儿腹泻的敷脐中药组合物 | |
| CN103735943B (zh) | 一种治疗泄泻的药物组合物及其制备方法和用途 | |
| CN100381156C (zh) | 治疗多汗症的药物 | |
| CN102302760B (zh) | 一种消食和胃中药组合物 | |
| CN103341150B (zh) | 一种治疗慢性胃炎的中药制剂 | |
| CN102949546A (zh) | 一种治疗胆囊炎胆结石的中药 | |
| CN101181568B (zh) | 一种治骨质增生及关节疼痛的中药制剂 | |
| CN102188685B (zh) | 一种治疗腹泻型肠易激综合征的中药外敷散剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C06 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130320 |
|
| C12 | Rejection of a patent application after its publication |